About
Gefitinib is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It works by reversibly binding to the ATP-binding site of the EGFR tyrosine kinase domain, thereby inhibiting the autophosphorylation of the receptor and the subsequent downstream signaling pathways involved in cell proliferation, survival, angiogenesis, and metastasis. Gefitinib is particularly effective in patients with non-small cell lung cancer (NSCLC) who have activating mutations in the EGFR gene, such as exon 19 deletions or L858R point mutations.
These activating mutations lead to constitutive activation of the EGFR pathway, driving tumor growth. By specifically targeting this mutated receptor, gefitinib can effectively block the growth signals in these cancer cells, leading to tumor regression and improved progression-free survival. It represents a significant advancement in personalized medicine for NSCLC, allowing for a more targeted and effective treatment approach for a specific patient population identified through biomarker testing.
Uses
- First-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.
- Treatment of patients with locally advanced or metastatic NSCLC who have previously received chemotherapy.
- Maintenance therapy for NSCLC after initial treatment.
- Used in specific patient populations identified by biomarker testing.
Directions For Use
Take orally once daily, with or without food. Swallow the tablet whole with water. Do not crush or chew.
Benefits
- Highly effective in NSCLC patients with activating EGFR mutations.
- Improves progression-free survival in targeted NSCLC populations.
- Offers a targeted therapy with a more favorable side effect profile than chemotherapy.
- Available as an oral tablet for convenient daily administration.
- Can lead to significant tumor response and symptom improvement.
- A key component of personalized medicine for lung cancer.
Side Effects
- Diarrhea
- Skin rash (acne-like)
- Dry skin
- Nausea and vomiting
- Anorexia (loss of appetite)
- Stomatitis (mouth sores)
- Conjunctivitis (eye inflammation)
- Interstitial lung disease (ILD) (rare but serious)
- Hepatotoxicity (liver damage)
- Proteinuria (protein in urine)
- Bleeding events
- Nail disorders
Safety Measures
- Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver-related side effects, a known risk with gefitinib.
- Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
- Breastfeeding - Not recommended during breastfeeding as gefitinib may be excreted in human milk and could harm the infant.
- Liver - Use with caution in patients with hepatic impairment; dose adjustment may be necessary. Monitor liver function tests regularly.
- Kidney - Use with caution in patients with severe renal impairment. Monitor renal function, though systemic exposure is generally low.
- Lung - Risk of interstitial lung disease (ILD), which can be severe or fatal. Monitor for new or worsening respiratory symptoms (e.g., dyspnea, cough, fever).
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!